Comment on: Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET/CT

Journal of Nuclear Medicine

Volumn 55, Issue 2, 2014, Pages 350-351

  Salavati, Ali ^a   Saboury, Babak ^a   Alavi, Abass ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; DIAGNOSTIC AGENT;

BODY WEIGHT; CANCER PROGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATIONAL STUDY; GLUCOSE BLOOD LEVEL; GLYCOLYSIS; HUMAN; LETTER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOLOGICAL PARAMETERS; STANDARDIZED UPTAKE VALUE; TUMOR VOLUME; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; MALE; MULTIMODAL IMAGING; NOTE; PANCREAS TUMOR; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MULTIMODAL IMAGING; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84897934177     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.130138     Document Type: Letter

References (11)

1. 18F-FDG PET/CT. J Nucl Med. 2013;54: 12-18.
2. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 2010;77: 1420-1425.
3. 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43: 173-180.
4. 18FDG uptake and expression of glucose transporter-1 and hexokinase II between low and high-risk tumors -preliminary study. Eur J Radiol. 2012;81: 146-151.
5. Van Steen K, Curran D, Kramer J, et al. Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection. Stat Med. 2002;21: 3865-3884.
6. Doot RK, Kurland BF, Kinahan PE, Mankoff DA. Design considerations for using PET as a response measure in single site and multicenter clinical trials. Acad Radiol. 2012;19: 184-190.
7. Houseni M, Chamroonrat W, Zhuang J, Gopal R, Alavi A, Zhuang H. Prognostic implication of dual-phase PET in adenocarcinoma of the lung. J Nucl Med. 2010;51: 535-542.
8. 18F- fluoro-2-deoxy-Dglucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2005;32: 389-397.
9. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med. 2012;53: 1506-1513.
10. 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med. 2012;53: 1829-1835.
11. Basu S, Kwee TC, Torigian D, Saboury B, Alavi A. Suboptimal and inadequate quantification: an alarming crisis in medical applications of PET. Eur J Nucl Med Mol Imaging. 2011;38: 1381-1382.